Show simple item record

dc.contributor.authorFotouhi, O
dc.contributor.authorKjellin, H
dc.contributor.authorLarsson, C
dc.contributor.authorHashemi, J
dc.contributor.authorBarriuso, J
dc.contributor.authorJuhlin, C
dc.contributor.authorLu, M
dc.contributor.authorHöög, A
dc.contributor.authorPastrián, L
dc.contributor.authorLamarca, Angela
dc.contributor.authorSoto, V
dc.contributor.authorZedenius, J
dc.contributor.authorMendiola, M
dc.contributor.authorLehtiö, J
dc.contributor.authorKjellman, M
dc.date.accessioned2016-10-12T13:01:06Z
dc.date.available2016-10-12T13:01:06Z
dc.date.issued2016-10
dc.identifier.citationProteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors. 2016, 101 (10):3616-3627 J Clin Endocrinol Metaben
dc.identifier.issn1945-7197
dc.identifier.pmid27459532
dc.identifier.doi10.1210/jc.2016-2028
dc.identifier.urihttp://hdl.handle.net/10541/619939
dc.description.abstractSomatostatin analogs are established in the treatment of neuroendocrine tumors (NETs) including small intestinal NET; however, the molecular mechanisms are not well known. Here, we examined the direct effects of lanreotide in NET cell line models.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to The Journal of clinical endocrinology and metabolismen
dc.titleProteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology-Pathology Karolinska Institutet, Stockholmen
dc.identifier.journalThe Journal of Clinical Endocrinology and Metabolismen
html.description.abstractSomatostatin analogs are established in the treatment of neuroendocrine tumors (NETs) including small intestinal NET; however, the molecular mechanisms are not well known. Here, we examined the direct effects of lanreotide in NET cell line models.


This item appears in the following Collection(s)

Show simple item record